Walid Abi‐Saab

4.3k total citations
42 papers, 3.3k citations indexed

About

Walid Abi‐Saab is a scholar working on Psychiatry and Mental health, Cellular and Molecular Neuroscience and Pharmacology. According to data from OpenAlex, Walid Abi‐Saab has authored 42 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Psychiatry and Mental health, 14 papers in Cellular and Molecular Neuroscience and 12 papers in Pharmacology. Recurrent topics in Walid Abi‐Saab's work include Neuroscience and Neuropharmacology Research (10 papers), Treatment of Major Depression (8 papers) and Neurotransmitter Receptor Influence on Behavior (7 papers). Walid Abi‐Saab is often cited by papers focused on Neuroscience and Neuropharmacology Research (10 papers), Treatment of Major Depression (8 papers) and Neurotransmitter Receptor Influence on Behavior (7 papers). Walid Abi‐Saab collaborates with scholars based in United States, United Kingdom and Switzerland. Walid Abi‐Saab's co-authors include John H. Krystal, Ralitza Gueorguieva, Steven Madonick, Thomas B. Cooper, Ayşenil Belger, Deepak Cyril D’Souza, Mario Saltarelli, Deepak Cyril D’Souza, Gabriel Braley and Kimberlee Forselius-Bielen and has published in prestigious journals such as The Lancet, Blood and Annals of Neurology.

In The Last Decade

Walid Abi‐Saab

41 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Walid Abi‐Saab United States	27	1.5k	906	800	787	539	42	3.3k
Petra Bittigau Germany	29	2.0k 1.3×	800 0.9×	477 0.6×	1.1k 1.5×	346 0.6×	42	6.4k
María J. Arranz United Kingdom	35	1.3k 0.9×	1.8k 2.0×	255 0.3×	1.2k 1.5×	455 0.8×	113	4.2k
Rajesh N. Kalaria United States	35	870 0.6×	507 0.6×	392 0.5×	1.3k 1.6×	350 0.6×	65	3.9k
Maria Barcikowska Poland	36	458 0.3×	718 0.8×	301 0.4×	1.5k 2.0×	278 0.5×	161	3.8k
Jeffrey D. Kennedy United States	26	524 0.4×	349 0.4×	517 0.6×	454 0.6×	324 0.6×	56	2.1k
Cinzia Costa Italy	39	2.1k 1.4×	1.6k 1.7×	268 0.3×	1.2k 1.5×	500 0.9×	113	4.8k
Stefan Vielhaber Germany	45	1.4k 0.9×	565 0.6×	187 0.2×	2.1k 2.7×	183 0.3×	166	5.8k
Carl‐Gerhard Gottfries Sweden	27	536 0.4×	609 0.7×	341 0.4×	633 0.8×	217 0.4×	57	2.4k
Atsuko Ikenouchi Japan	27	672 0.5×	475 0.5×	353 0.4×	226 0.3×	452 0.8×	136	2.3k
Paul G. Unschuld Switzerland	29	1.1k 0.7×	396 0.4×	141 0.2×	838 1.1×	525 1.0×	76	3.0k

Countries citing papers authored by Walid Abi‐Saab

Since Specialization

Citations

This map shows the geographic impact of Walid Abi‐Saab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Walid Abi‐Saab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Walid Abi‐Saab more than expected).

Fields of papers citing papers by Walid Abi‐Saab

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Walid Abi‐Saab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Walid Abi‐Saab. The network helps show where Walid Abi‐Saab may publish in the future.

Co-authorship network of co-authors of Walid Abi‐Saab

This figure shows the co-authorship network connecting the top 25 collaborators of Walid Abi‐Saab. A scholar is included among the top collaborators of Walid Abi‐Saab based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Walid Abi‐Saab. Walid Abi‐Saab is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heijde, Désirée van der, Xenofon Baraliakos, Lianne S. Gensler, et al.. (2018). Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. The Lancet. 392(10162). 2378–2387. 194 indexed citations

Wood, John C., et al.. (2015). Liver MRI is more precise than liver biopsy for assessing total body iron balance: a comparison of MRI relaxometry with simulated liver biopsy results. Magnetic Resonance Imaging. 33(6). 761–767. 48 indexed citations

Bain, Earle, Weining Robieson, Yili Pritchett, et al.. (2012). A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of α4β2 Agonist ABT-894 in Adults with ADHD. Neuropsychopharmacology. 38(3). 405–413. 46 indexed citations

Lenz, Robert, Jeffrey D. Baker, Charles Locke, et al.. (2011). The scopolamine model as a pharmacodynamic marker in early drug development. Psychopharmacology. 220(1). 97–107. 47 indexed citations

Berg, Daniela, Jana Godau, Claudia Trenkwalder, et al.. (2011). AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials. Movement Disorders. 26(7). 1243–1250. 145 indexed citations

Wilens, Timothy E., Laura M. Gault, Ann Childress, et al.. (2010). Safety and Efficacy of ABT-089 in Pediatric Attention-Deficit/Hyperactivity Disorder: Results from Two Randomized Placebo-Controlled Clinical Trials. Journal of the American Academy of Child & Adolescent Psychiatry. 50(1). 73–84.e1. 32 indexed citations

Redden, Laura, Melissa P. DelBello, Karen Dineen Wagner, et al.. (2009). Long-Term Safety of Divalproex Sodium Extended-Release in Children and Adolescents with Bipolar I Disorder. Journal of Child and Adolescent Psychopharmacology. 19(1). 83–89. 27 indexed citations

Graff‐Guerrero, Ariel, Laura Redden, Walid Abi‐Saab, et al.. (2009). Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. The International Journal of Neuropsychopharmacology. 13(3). 273–273. 57 indexed citations

Apostol, George, Roger Cady, Genevieve Laforet, et al.. (2008). Divalproex Extended‐Release in Adolescent Migraine Prophylaxis: Results of a Randomized, Double‐Blind, Placebo‐Controlled Study. Headache The Journal of Head and Face Pain. 48(7). 1012–1025. 43 indexed citations

10.

Casey, Daniel E., David G. Daniel, Carol A. Tamminga, et al.. (2008). Divalproex ER Combined with Olanzapine or Risperidone for Treatment of Acute Exacerbations of Schizophrenia. Neuropsychopharmacology. 34(5). 1330–1338. 41 indexed citations

11.

Çavuş, Idil, Jullie W. Pan, Hoby P. Hetherington, et al.. (2008). Decreased hippocampal volume on MRI is associated with increased extracellular glutamate in epilepsy patients. Epilepsia. 49(8). 1358–1366. 75 indexed citations

12.

Apostol, George, Ann Pakalnis, Genevieve Laforet, et al.. (2008). Safety and Tolerability of Divalproex Sodium Extended‐Release in the Prophylaxis of Migraine Headaches: Results of an Open‐Label Extension Trial in Adolescents. Headache The Journal of Head and Face Pain. 49(1). 36–44. 17 indexed citations

13.

Bowden, Charles L., Alan C. Swann, Joseph R. Calabrese, et al.. (2006). A Randomized, Placebo-Controlled, Multicenter Study of Divalproex Sodium Extended Release in the Treatment of Acute Mania. The Journal of Clinical Psychiatry. 67(10). 1501–1510. 87 indexed citations

14.

D’Souza, Deepak Cyril, Walid Abi‐Saab, Steven Madonick, et al.. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biological Psychiatry. 57(6). 594–608. 452 indexed citations

15.

Cho, Hyun Sang, Deepak Cyril D’Souza, Ralitza Gueorguieva, et al.. (2005). Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine. Psychopharmacology. 179(1). 136–143. 33 indexed citations

16.

Krystal, John H., Edward Perry, Ralitza Gueorguieva, et al.. (2005). Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine. Archives of General Psychiatry. 62(9). 985–985. 258 indexed citations

17.

Abi‐Saab, Walid, John Seibyl, Cyril D’Souza, et al.. (2002). Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology. 162(1). 55–62. 18 indexed citations

18.

Conejero‐Goldberg, Concepcion, Carlo Tornatore, Walid Abi‐Saab, et al.. (2000). Transduction of Human GAD67 cDNA into Immortalized Striatal Cell Lines Using an Epstein–Barr Virus-Based Plasmid Vector Increases GABA Content. Experimental Neurology. 161(2). 453–461. 20 indexed citations

19.

Abi‐Saab, Walid. (1999). 5-HT2 Receptor Regulation of Extracellular GABA Levels in the Prefrontal Cortex. Neuropsychopharmacology. 20(1). 92–96. 141 indexed citations

20.

Abi‐Saab, Walid, Deepak Cyril D’Souza, Bita Moghaddam, & John H. Krystal. (1998). The NMDA Antagonist Model for Schizophrenia: Promise and Pitfalls. Pharmacopsychiatry. 31(S 2). 104–109. 163 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact